This was Shark Tank India, Season 1, Episode 32; C3 Med-Tech Private Limited. I spoke as a shark during the pitch, and the transcript distinguishes my words from other speakers’ remarks, which are included only for context and are not my words or views.
I volunteered to participate in the demonstration, asked whether the technology was made in India, and questioned why Yash was doing the work and whether he had relevant experience. I said, “Main aana chahta hoon,” and asked, “India mein banaya hai tech aapne?”
Yash Nagarsheth said his master’s thesis at the University of Michigan, Ann Arbor, was in telemedicine; he learned to design hardware for low-resource areas and the “less is more” concept. His words included: “Mera Masters thesis telemedicine mein tha. Wahan pe main seekha ke aap hardware kaise design karte hain low resource areas ke liye, less is more ka jo concept hai, woh seekh ke ye maine banaya hai.”
I said a slit lamp costs 75,000 rupe in India; Yash stated 26,000 as an introductory price and said they would work on price at scale. I challenged the claim that ₹26,000 was cheap and asked what the whole device currently cost to make.
I cited 600 million people in India with eye problems and questioned equipment financing, end value, and the business model because the device neither sells glasses nor determines prescription power. I said, “Na chashma bech sakte, isse power toh aap nikal nahi rahe.”
I said the checkup could only be done by an ophthalmologist, not a regular optometrist, although I did not think it required a doctor’s specific expertise. I raised the allied healthcare rules and asked, “Socha aapne is baare mein?”
I said AI software could recognize patterns and estimate likelihood of diabetic retinopathy, glaucoma, or cataract, but nobody had perfected it. I distinguished image capture from vision correction and diagnosis.
I said investors might shift companies toward sales after devices sold, leaving too little money for research and development; I also described ophthalmology as a large, profitable business for an ophthalmologist. My examples included companies having sold 500 device or 100 bech diye. I agreed with Namita that the issue was global and said companies had sold devices, expected a business to emerge, and encountered saturation.
Yash said C3 Med-Tech had sold 22 lakhs. After asking how much they had sold, I said I would advise them not to sell for now.
I advised the founders to focus on one problem, such as cataract or diabetic retinopathy, and build the world’s best and cheapest device for it; I said 26,000 was not cheap enough for India. My approach was to solve a specific major eye-health problem rather than prioritize device sales.
Alisha Nagarsheth stated an ask of 35 lakhs. I offered 35 lakh for 1/3rd equity and said further investment would need to be considered.
I said I had confidence in myself, more than in the founders, to focus them on solving the problem rather than selling the device. I explained that I believed I could keep them focused on the problem.
I offered help with customer trials, focus, optometrist testing, feedback, and data collection that could support a future AI layer; I said the area was related to vision but distinct from my business’s problem. I said my optometrists could try the products and provide feedback, and that collected data could support building an AI layer later.
I rejected the founders’ proposed 15% 20% range, saying no, because substantial work remained and I could not see a revenue stream. I said, “Aapka 1/3rd is non-negotiable.”
The transcript ends without establishing whether the founders accepted my offer. It also leaves open the device’s actual current manufacturing cost, the meaning of Yash’s “around 4 to 5 lakhs” estimate, the eventual price at scale, and which problem the company would prioritize. I questioned the device’s end value, financing path, and revenue model; the discussion does not resolve how allied healthcare rules would affect who could conduct the checkup or whether a reliable diagnostic AI layer could be developed.
I said that many startups in this phase do not solve the problem: “Bahut startups hain, aur is phase mein na, koi solve karta nahi hai.”
I compared equipment financing with car financing, saying a bank finances an Ola driver’s car but nobody finances equipment: “Aaj aap gaadi lene jaate hain na jab Ola driver hota hai, woh gaadi lete jaata hai toh bank finance kar deta hai gaadi. Jab aap equipment leke jaate hain toh koi finance nahi karta”.
Yash Nagarsheth said, “Ye hoga around 4 to 5 lakhs ka.” The transcript does not establish what this estimate referred to.